View ValuationStarpharma Holdings 향후 성장Future 기준 점검 6/6Starpharma Holdings (는) 각각 연간 91.8% 및 39.5% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 91.3% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 756% 로 예상됩니다.핵심 정보91.8%이익 성장률91.27%EPS 성장률Pharmaceuticals 이익 성장14.5%매출 성장률39.5%향후 자기자본이익률756.05%애널리스트 커버리지Low마지막 업데이트02 Apr 2026최근 향후 성장 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Sep 18Starpharma Holdings Limited, Annual General Meeting, Nov 14, 2025Starpharma Holdings Limited, Annual General Meeting, Nov 14, 2025.공시 • Oct 03Starpharma Holdings Limited, Annual General Meeting, Nov 26, 2024Starpharma Holdings Limited, Annual General Meeting, Nov 26, 2024.공시 • Nov 11+ 1 more updateStarpharma Holdings Limited Appoints Cheryl Maley as Chief Executive Officer, Effective 8 January 2024Starpharma Holdings Limited announced the appointment of Ms. Cheryl Maley as Chief Executive Officer (CEO) of Starpharma effective 8 January 2024. Cheryl has over 25 years of experience in the pharmaceutical industry, including 20 years in leadership roles at well-known and leading organisations, including Novartis and AbbVie/Abbott. Her roles include nine years at Novartis in senior commercial and executive roles and various sales and marketing positions with AbbVie/Abbott, Servier Laboratories, and Wyeth Pharmaceuticals. Cheryl has had extensive experience in leading pharmaceutical innovation, marketing, commercialisation and delivering business growth across Australia, Asia, and international markets. She has a strong commercial background with a proven record in successful product launches and patient access and reimbursement to innovative medicines.공시 • Oct 02Starpharma Holdings Limited, Annual General Meeting, Nov 29, 2023Starpharma Holdings Limited, Annual General Meeting, Nov 29, 2023, at 14:00 AUS Eastern Standard Time.공시 • Sep 19Starpharma Holdings Limited Announces Viraleze for Respiratory and Cold VirusesThis winter, in order to maximise defences against respiratory viruses, VIRALEZE nasal spray is available to provide a protective barrier against a broad spectrum of respiratory viruses. VIRALEZE has shown the ability to trap and block a wide range and multiple strains of respiratory and cold viruses. Key Features of VIRALEZE Barrier Nasal Spray: Barrier Formulation: VIRALEZE is specifically designed to target the nose where respiratory viruses first attach and multiply. It provides a protective physical barrier in the nose that is intended to trap and block respiratory and cold viruses before an infection develops, helping to reduce exposure to virus. Broad-Spectrum: VIRALEZE traps and blocks a wide range of respiratory viruses, including common cold and flu viruses. Its physical mechanism of action means it traps and blocks a broad spectrum of respiratory and cold viruses, including emerging viruses and strains. Scientifically Proven: Rigorous laboratory studies have demonstrated the ability of VIRALEZE to trap and block respiratory and cold viruses, and to reduce the incidence and severity of respiratory virus infection in stringent models. User-Friendly Application: VIRALEZE is easy to use and store at room temperature, making it easy to incorporate into daily routines. With a simple application, individuals can take proactive steps to safeguard their respiratory health. Useful in a variety of settings: The use of VIRALEZE fits seamlessly into various lifestyles, including work, travel and commuting, and leisure activities, such as attending sports and music events. Its non-invasive application ensures that VIRALEZE does not impact daily life. Starpharma is also currently completing a post-market study of VIRALEZE™ at St Peter's Hospital, UK, where its ability to reduce viral load in COVID-19-positive patients is being evaluated.공시 • Aug 28Starpharma Holdings Limited Announces Change of Company SecretaryStarpharma Holdings Limited announced, in accordance with ASX Listing Rule 3.16.1, that Tracy Weimar has resigned as Company Secretary, a role that was conducted for an interim period. Justin Cahill, Starpharma's Chief Financial Officer and Company Secretary, continues as the person responsible for communication with ASX under ASX Listing Rule 12.6.New Risk • Jun 23New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: US$99.1m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings have declined by 9.7% per year over the past 5 years. Minor Risks Revenue is less than US$5m (AU$4.7m revenue, or US$3.2m). Market cap is less than US$100m (US$99.1m market cap).공시 • Jun 09Starpharma Announces Resignation of Jackie Fairley as Chief Executive OfficerStarpharma announced that following her significant tenure as the Company's Chief Executive Officer, Dr. Jackie Fairley has advised the Board that she intends to retire during 2024. Jackie and the Board are keen to ensure an orderly transition and have agreed that she will continue in the role until a successor is ready to commence, providing leadership and continuity throughout the transition period.공시 • Feb 02Starpharma Holdings Limited Announces Board ChangesStarpharma Holdings Limited announced that Ms Tracy Weimar from Vistra Australia has been appointed as interim Company Secretary, effective 1 February 2023. Ms Weimar is a Fellow of the Governance Institute of Australia (FGIA) and a Graduate of the Australian Institute of Company Directors (GAICD), with over 20 years of commercial, company secretarial and non-executive director experience in the pharmaceutical/biotech industry in both the large and small cap sectors. Ms Weimar is currently a Company Secretary of, and provides company secretarial services to, various ASX listed, unlisted public and private companies, predominately in biotechnology. With Ms Weimar's appointment, Mr. Nigel Baade will step down as Company Secretary of the Company, effective 1 February 2023. Mr. Baade will continue in the role of Chief Financial Officer (CFO) until his departure in March 2023, as previously announced on 21 December 2022. Starpharma is well advanced in its search for a replacement CFO /Company Secretary and will update the market at the conclusion of this process.공시 • Jan 31Starpharma Holdings Limited Appoints Russell Basser as Non-Executive Director, Effective from 20 February 2023The Board of Starpharma Holdings Limited announced the appointment of Dr. Russell Basser as an independent non-executive director, effective from 20 February 2023. Dr Basser is a medical oncologist and former corporate executive with over 30 years of international medical and biopharmaceutical experience, including 21 years at CSL. Dr. Basser has substantial expertise in international drug and vaccine development, having held multiple senior executive roles whilst at CSL, including Senior Vice President (SVP) of Research and Development at CSL Seqirus; Chief Medical Officer at CSL Limited /CSL Behring; and SVP of Global Clinical Research and Development at CSL Behring /CSL Limited. As SVP of Global Clinical Research and Development at CSL Behring, Dr Basser was responsible for globalising CSL's Clinical Research and Development group, and for conception and execution of CSL's clinical trial strategies across a broad range of therapeutic areas from Phase 1 through to commercialisation. Dr Basser was a founding member of CSL Seqirus' executive leadership team in 2015 as SVP of Research and Development until his retirement in April 2022. In this role, he was responsible for all R&D activities through to commercialisation, including new global registrations of CSL Seqirus' seasonal, pre-pandemic and pandemic influenza vaccines, major process improvements and annual influenza vaccine updates. He also had oversight of the establishment of the framework for real world effectiveness evaluation that led to enhanced understanding of the health benefits of differentiated influenza vaccines. Prior to joining CSL, Dr Basser was a practicing medical oncologist at the Royal Melbourne and Western Hospitals and had an appointment at the Ludwig Institute for Cancer Research. He also worked as an Experimental Medicine Physician for AstraZeneca in the UK and was the Director of the Centre for Developmental Cancer Therapeutics (now Cancer Trials Australia) for seven years.이익 및 매출 성장 예측OTCPK:SPHR.F - 애널리스트 향후 추정치 및 과거 재무 데이터 (AUD Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수6/30/202838139916/30/2027240-3-316/30/202616-4-4-4112/31/202515-3-1-1N/A9/30/202510-7-4-4N/A6/30/20256-10-7-7N/A3/31/20255-11-9-9N/A12/31/20244-13-11-11N/A9/30/20247-10-9-9N/A6/30/202410-8-7-7N/A3/31/202410-8-7-7N/A12/31/202311-8-7-7N/A9/30/20238-12-11-11N/A6/30/20234-16-15-14N/A3/31/20235-16-12-11N/A12/31/20225-16-8-7N/A9/30/20225-16-11-10N/A6/30/20225-16-14-13N/A3/31/20225-17-18-17N/A12/31/20214-18-21-21N/A9/30/20214-19-18-18N/A6/30/20213-20-15-15N/A3/31/20213-19-13-13N/A12/31/20203-19-11-11N/A9/30/20205-17-11-11N/A6/30/20207-15-11-11N/A3/31/20207-14-10-10N/A12/31/20198-13-8-8N/A9/30/20195-14N/A-9N/A6/30/20193-14N/A-10N/A3/31/20194-13N/A-8N/A12/31/20184-11N/A-6N/A9/30/20185-11N/A-8N/A6/30/20185-10N/A-10N/A3/31/20185-12N/AN/AN/A12/31/20174-13N/A-18N/A9/30/20174-14N/A-18N/A6/30/20174-15N/A-17N/A12/31/20161-20N/A-20N/A9/30/20163-20N/A-19N/A6/30/20165-21N/A-18N/A3/31/20165-22N/A-17N/A12/31/20155-20N/A-16N/A9/30/20153-20N/A-15N/A6/30/20152-19N/A-14N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: SPHR.F 은 향후 3년 동안 수익을 낼 것으로 예상되며, 이는 절약률(3.5%)보다 빠른 성장으로 간주됩니다.수익 vs 시장: SPHR.F (는) 향후 3년 동안 평균 시장 성장보다 높은 수익을 올릴 것으로 예상됩니다.고성장 수익: SPHR.F 향후 3년 내에 수익을 낼 것으로 예상됩니다.수익 대 시장: SPHR.F 의 수익(연간 39.5%)이 US 시장(연간 11.8%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: SPHR.F 의 수익(연간 39.5%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: SPHR.F의 자본 수익률은 3년 후 756%로 매우 높을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/26 04:28종가2026/05/18 00:00수익2025/12/31연간 수익2025/06/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Starpharma Holdings Limited는 9명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Matthijs SmithCanaccord GenuityDerek JellinekCGS InternationalWaradana Malitha De SilvaCLSA6명의 분석가 더 보기
공시 • Sep 18Starpharma Holdings Limited, Annual General Meeting, Nov 14, 2025Starpharma Holdings Limited, Annual General Meeting, Nov 14, 2025.
공시 • Oct 03Starpharma Holdings Limited, Annual General Meeting, Nov 26, 2024Starpharma Holdings Limited, Annual General Meeting, Nov 26, 2024.
공시 • Nov 11+ 1 more updateStarpharma Holdings Limited Appoints Cheryl Maley as Chief Executive Officer, Effective 8 January 2024Starpharma Holdings Limited announced the appointment of Ms. Cheryl Maley as Chief Executive Officer (CEO) of Starpharma effective 8 January 2024. Cheryl has over 25 years of experience in the pharmaceutical industry, including 20 years in leadership roles at well-known and leading organisations, including Novartis and AbbVie/Abbott. Her roles include nine years at Novartis in senior commercial and executive roles and various sales and marketing positions with AbbVie/Abbott, Servier Laboratories, and Wyeth Pharmaceuticals. Cheryl has had extensive experience in leading pharmaceutical innovation, marketing, commercialisation and delivering business growth across Australia, Asia, and international markets. She has a strong commercial background with a proven record in successful product launches and patient access and reimbursement to innovative medicines.
공시 • Oct 02Starpharma Holdings Limited, Annual General Meeting, Nov 29, 2023Starpharma Holdings Limited, Annual General Meeting, Nov 29, 2023, at 14:00 AUS Eastern Standard Time.
공시 • Sep 19Starpharma Holdings Limited Announces Viraleze for Respiratory and Cold VirusesThis winter, in order to maximise defences against respiratory viruses, VIRALEZE nasal spray is available to provide a protective barrier against a broad spectrum of respiratory viruses. VIRALEZE has shown the ability to trap and block a wide range and multiple strains of respiratory and cold viruses. Key Features of VIRALEZE Barrier Nasal Spray: Barrier Formulation: VIRALEZE is specifically designed to target the nose where respiratory viruses first attach and multiply. It provides a protective physical barrier in the nose that is intended to trap and block respiratory and cold viruses before an infection develops, helping to reduce exposure to virus. Broad-Spectrum: VIRALEZE traps and blocks a wide range of respiratory viruses, including common cold and flu viruses. Its physical mechanism of action means it traps and blocks a broad spectrum of respiratory and cold viruses, including emerging viruses and strains. Scientifically Proven: Rigorous laboratory studies have demonstrated the ability of VIRALEZE to trap and block respiratory and cold viruses, and to reduce the incidence and severity of respiratory virus infection in stringent models. User-Friendly Application: VIRALEZE is easy to use and store at room temperature, making it easy to incorporate into daily routines. With a simple application, individuals can take proactive steps to safeguard their respiratory health. Useful in a variety of settings: The use of VIRALEZE fits seamlessly into various lifestyles, including work, travel and commuting, and leisure activities, such as attending sports and music events. Its non-invasive application ensures that VIRALEZE does not impact daily life. Starpharma is also currently completing a post-market study of VIRALEZE™ at St Peter's Hospital, UK, where its ability to reduce viral load in COVID-19-positive patients is being evaluated.
공시 • Aug 28Starpharma Holdings Limited Announces Change of Company SecretaryStarpharma Holdings Limited announced, in accordance with ASX Listing Rule 3.16.1, that Tracy Weimar has resigned as Company Secretary, a role that was conducted for an interim period. Justin Cahill, Starpharma's Chief Financial Officer and Company Secretary, continues as the person responsible for communication with ASX under ASX Listing Rule 12.6.
New Risk • Jun 23New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: US$99.1m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings have declined by 9.7% per year over the past 5 years. Minor Risks Revenue is less than US$5m (AU$4.7m revenue, or US$3.2m). Market cap is less than US$100m (US$99.1m market cap).
공시 • Jun 09Starpharma Announces Resignation of Jackie Fairley as Chief Executive OfficerStarpharma announced that following her significant tenure as the Company's Chief Executive Officer, Dr. Jackie Fairley has advised the Board that she intends to retire during 2024. Jackie and the Board are keen to ensure an orderly transition and have agreed that she will continue in the role until a successor is ready to commence, providing leadership and continuity throughout the transition period.
공시 • Feb 02Starpharma Holdings Limited Announces Board ChangesStarpharma Holdings Limited announced that Ms Tracy Weimar from Vistra Australia has been appointed as interim Company Secretary, effective 1 February 2023. Ms Weimar is a Fellow of the Governance Institute of Australia (FGIA) and a Graduate of the Australian Institute of Company Directors (GAICD), with over 20 years of commercial, company secretarial and non-executive director experience in the pharmaceutical/biotech industry in both the large and small cap sectors. Ms Weimar is currently a Company Secretary of, and provides company secretarial services to, various ASX listed, unlisted public and private companies, predominately in biotechnology. With Ms Weimar's appointment, Mr. Nigel Baade will step down as Company Secretary of the Company, effective 1 February 2023. Mr. Baade will continue in the role of Chief Financial Officer (CFO) until his departure in March 2023, as previously announced on 21 December 2022. Starpharma is well advanced in its search for a replacement CFO /Company Secretary and will update the market at the conclusion of this process.
공시 • Jan 31Starpharma Holdings Limited Appoints Russell Basser as Non-Executive Director, Effective from 20 February 2023The Board of Starpharma Holdings Limited announced the appointment of Dr. Russell Basser as an independent non-executive director, effective from 20 February 2023. Dr Basser is a medical oncologist and former corporate executive with over 30 years of international medical and biopharmaceutical experience, including 21 years at CSL. Dr. Basser has substantial expertise in international drug and vaccine development, having held multiple senior executive roles whilst at CSL, including Senior Vice President (SVP) of Research and Development at CSL Seqirus; Chief Medical Officer at CSL Limited /CSL Behring; and SVP of Global Clinical Research and Development at CSL Behring /CSL Limited. As SVP of Global Clinical Research and Development at CSL Behring, Dr Basser was responsible for globalising CSL's Clinical Research and Development group, and for conception and execution of CSL's clinical trial strategies across a broad range of therapeutic areas from Phase 1 through to commercialisation. Dr Basser was a founding member of CSL Seqirus' executive leadership team in 2015 as SVP of Research and Development until his retirement in April 2022. In this role, he was responsible for all R&D activities through to commercialisation, including new global registrations of CSL Seqirus' seasonal, pre-pandemic and pandemic influenza vaccines, major process improvements and annual influenza vaccine updates. He also had oversight of the establishment of the framework for real world effectiveness evaluation that led to enhanced understanding of the health benefits of differentiated influenza vaccines. Prior to joining CSL, Dr Basser was a practicing medical oncologist at the Royal Melbourne and Western Hospitals and had an appointment at the Ludwig Institute for Cancer Research. He also worked as an Experimental Medicine Physician for AstraZeneca in the UK and was the Director of the Centre for Developmental Cancer Therapeutics (now Cancer Trials Australia) for seven years.